Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Shares Outstanding (2016 - 2025)

Apyx Medical (APYX) has disclosed Shares Outstanding for 16 consecutive years, with $41.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 10.56% year-over-year to $41.8 million, compared with a TTM value of $41.8 million through Dec 2025, up 10.56%, and an annual FY2025 reading of $41.8 million, up 10.56% over the prior year.
  • Shares Outstanding was $41.8 million for Q4 2025 at Apyx Medical, up from $37819.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $41.8 million in Q4 2025 and bottomed at $37819.0 in Q3 2025.
  • Average Shares Outstanding over 5 years is $33.7 million, with a median of $34.6 million recorded in 2022.
  • Peak annual rise in Shares Outstanding hit 10.56% in 2025, while the deepest fall reached 99.89% in 2025.
  • Year by year, Shares Outstanding stood at $34.4 million in 2021, then increased by 0.55% to $34.6 million in 2022, then grew by 0.13% to $34.6 million in 2023, then rose by 9.09% to $37.8 million in 2024, then rose by 10.56% to $41.8 million in 2025.
  • Business Quant data shows Shares Outstanding for APYX at $41.8 million in Q4 2025, $37819.0 in Q3 2025, and $37.8 million in Q2 2025.